Immunofoco’s Lentiviral Strategy for Cancer Control
Revolutionizing Cancer Treatment: Immunofoco's Approach In the battle against B-cell malignancies, the old ways of doing things sometimes just don’t cut it, folks. Enter Immunofoco. At the recent Society for Immunotherapy of Cancer (SITC) 2026 meeting, they laid some ambitious cards on the table with their in vivo T-cell engager (TCE) delivery strategy. Engineering...
Continue Reading